Zymeworks Inc. Insider Trading

ZYME

Last 12 months

Insiders sold $5.03M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chair & CEO Kenneth Galbraith sold $1.36M on Jan 5, 22% of their stake, outside a plan. The last open-market buy by an executive or director was in Apr 2025.

Net open-market

−$5.03M

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Apr 2025

Apr 4, 2025

Get an email when ZYME's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 9	Adam Schayowitz EVP, Head of R&D	SoldNo plan	13,832	$25.85	358K	37%	Form 4
Jan 12	Mark Hollywood EVP & Chief Operating Officer	SoldNo plan	6,120	$22.67	139K	4.4%	Form 4
Jan 12	Jeffrey T L Smith EVP & Chief Medical Officer	SoldNo plan	9,310	$22.67	211K	26%	Form 4
Jan 12	Paul Andrew Moore Chief Scientific Officer	SoldNo plan	9,560	$22.67	217K	16%	Form 4
Jan 12	Kenneth Galbraith Chair & CEO	SoldNo plan	30,424	$22.67	690K	12%	Form 4
Jan 5	Jeffrey T L Smith EVP & Chief Medical Officer	SoldNo plan	10,538	$25.10	265K	36%	Form 4
Jan 5	Kenneth Galbraith Chair & CEO	SoldNo plan 2 parts	54,343	$25.10 average	$1.36M	22%	Form 4
Jan 5	Paul Andrew Moore Chief Scientific Officer	SoldNo plan 2 parts	20,110	$25.10 average	505K	33%	Form 4
Dec 22, 2025	Kenneth Galbraith Chair & CEO	SoldNo plan	47,528	$27.02	$1.28M	26%	Form 4
May 15, 2025 – May 19, 2025	Ecor1 Capital, LLC Large holder	Bought 2 parts	55,421	$11.47 average	636K	0.3%	Form 4
Apr 16, 2025 – Apr 17, 2025	Ecor1 Capital, LLC Large holder	Bought 2 parts	128,713	$11.31 average	$1.46M	0.7%	Form 4
Apr 3, 2025 – Apr 4, 2025	Oleg Nodelman Director	Bought 2 parts	317,208	$11.43 average	$3.62M	1.8%	Form 4
Mar 31, 2025 – Apr 2, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	127,415	$11.75 average	$1.5M	0.7%	Form 4
Mar 25, 2025 – Mar 26, 2025	Ecor1 Capital, LLC Large holder	Bought 2 parts	97,349	$12.61 average	$1.23M	0.6%	Form 4
Mar 20, 2025 – Mar 24, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	127,198	$12.92 average	$1.64M	0.7%	Form 4
Mar 17, 2025 – Mar 19, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	228,463	$12.54 average	$2.87M	1.4%	Form 4
Mar 11, 2025 – Mar 13, 2025	Oleg Nodelman Director	Bought 3 parts	1,081,980	$12.12 average	$13.1M	6.9%	Form 4
Jan 16, 2025 – Jan 17, 2025	Ecor1 Capital, LLC Large holder	Bought 2 parts	141,429	$13.89 average	$1.96M	0.9%	Form 4
Jan 13, 2025 – Jan 15, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	167,654	$13.59 average	$2.28M	1.1%	Form 4
Jan 8, 2025 – Jan 10, 2025	Ecor1 Capital, LLC Large holder	Bought 2 parts	225,119	$13.22 average	$2.98M	1.5%	Form 4
Jan 6, 2025	Paul Andrew Moore Chief Scientific Officer	SoldNo plan 2 parts	21,200	$14.92 average	316K	48%	Form 4
Jan 6, 2025	Kenneth Galbraith Chair & CEO	SoldNo plan 2 parts	57,291	$14.92 average	855K	41%	Form 4
Jan 6, 2025	Jeffrey T L Smith EVP & Chief Medical Officer	SoldNo plan	11,110	$14.92	166K	56%	Form 4
Dec 30, 2024 – Jan 2, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	363,369	$14.65 average	$5.32M	2.5%	Form 4
Dec 24, 2024 – Dec 27, 2024	Ecor1 Capital, LLC Large holder	Bought 3 parts	130,309	$14.44 average	$1.88M	0.9%	Form 4
Dec 19, 2024 – Dec 23, 2024	Ecor1 Capital, LLC Large holder	Bought 3 parts	1,254,808	$13.98 average	$17.5M	9.3%	Form 4

Oct 9No plan
Adam Schayowitz
EVP, Head of R&D · sold 13,832 at $25.85
358K
37% of stake
Jan 12No plan
Mark Hollywood
EVP & Chief Operating Officer · sold 6,120 at $22.67
139K
4.4% of stake
Jan 12No plan
Jeffrey T L Smith
EVP & Chief Medical Officer · sold 9,310 at $22.67
211K
26% of stake
Jan 12No plan
Paul Andrew Moore
Chief Scientific Officer · sold 9,560 at $22.67
217K
16% of stake
Jan 12No plan
Kenneth Galbraith
Chair & CEO · sold 30,424 at $22.67
690K
12% of stake
Jan 5No plan
Jeffrey T L Smith
EVP & Chief Medical Officer · sold 10,538 at $25.10
265K
36% of stake
Jan 5No plan
Kenneth Galbraith
Chair & CEO · sold 54,343 at avg $25.10
$1.36M
22% of stake
Jan 5No plan
Paul Andrew Moore
Chief Scientific Officer · sold 20,110 at avg $25.10
505K
33% of stake
Dec 22, 2025No plan
Kenneth Galbraith
Chair & CEO · sold 47,528 at $27.02
$1.28M
26% of stake
May 15, 2025 – May 19, 2025
Ecor1 Capital, LLC
Large holder · bought 55,421 at avg $11.47
636K
0.3% of stake
Apr 16, 2025 – Apr 17, 2025
Ecor1 Capital, LLC
Large holder · bought 128,713 at avg $11.31
$1.46M
0.7% of stake
Apr 3, 2025 – Apr 4, 2025
Oleg Nodelman
Director · bought 317,208 at avg $11.43
$3.62M
1.8% of stake
Mar 31, 2025 – Apr 2, 2025
Ecor1 Capital, LLC
Large holder · bought 127,415 at avg $11.75
$1.5M
0.7% of stake
Mar 25, 2025 – Mar 26, 2025
Ecor1 Capital, LLC
Large holder · bought 97,349 at avg $12.61
$1.23M
0.6% of stake
Mar 20, 2025 – Mar 24, 2025
Ecor1 Capital, LLC
Large holder · bought 127,198 at avg $12.92
$1.64M
0.7% of stake
Mar 17, 2025 – Mar 19, 2025
Ecor1 Capital, LLC
Large holder · bought 228,463 at avg $12.54
$2.87M
1.4% of stake
Mar 11, 2025 – Mar 13, 2025
Oleg Nodelman
Director · bought 1,081,980 at avg $12.12
$13.1M
6.9% of stake
Jan 16, 2025 – Jan 17, 2025
Ecor1 Capital, LLC
Large holder · bought 141,429 at avg $13.89
$1.96M
0.9% of stake
Jan 13, 2025 – Jan 15, 2025
Ecor1 Capital, LLC
Large holder · bought 167,654 at avg $13.59
$2.28M
1.1% of stake
Jan 8, 2025 – Jan 10, 2025
Ecor1 Capital, LLC
Large holder · bought 225,119 at avg $13.22
$2.98M
1.5% of stake
Jan 6, 2025No plan
Paul Andrew Moore
Chief Scientific Officer · sold 21,200 at avg $14.92
316K
48% of stake
Jan 6, 2025No plan
Kenneth Galbraith
Chair & CEO · sold 57,291 at avg $14.92
855K
41% of stake
Jan 6, 2025No plan
Jeffrey T L Smith
EVP & Chief Medical Officer · sold 11,110 at $14.92
166K
56% of stake
Dec 30, 2024 – Jan 2, 2025
Ecor1 Capital, LLC
Large holder · bought 363,369 at avg $14.65
$5.32M
2.5% of stake
Dec 24, 2024 – Dec 27, 2024
Ecor1 Capital, LLC
Large holder · bought 130,309 at avg $14.44
$1.88M
0.9% of stake
Dec 19, 2024 – Dec 23, 2024
Ecor1 Capital, LLC
Large holder · bought 1,254,808 at avg $13.98
$17.5M
9.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ZYME, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ZYME

CompareIntrinsic value

VTVTvTv Therapeutics Inc.

$24.03+2.04%40

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

FHTXFoghorn Therapeutics Inc.

$2.10-1.41%40

CUECue Biopharma, Inc.

$19.84-4.89%40

ETSTEarth Science Tech Inc.

$0.10+0.00%72

SBFMSunshine Biopharma Inc.

$2.65-3.28%40

LIFDLftd Partners Inc.

$0.11+0.00%35

ZOMDFZomedica Corp.

$0.09-1.08%46

Held by ETFs

ZYME is in 40 US ETFs. The largest of them, with ZYME's weight in each:

Spot a number that looks wrong? Check it in ZYME's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ZYME

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.